In the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial that compared rivaroxaban to vitamin K antagonists in patients with non-valvular AF, patients with paroxysmal AF had 21% lower all-cause mortality compared to patients with persistent AF [24]. This evidence concerns the gene F10 and Paroxysmal atrial fibrillation.